New biomarkers for the non-invasive diagnosis of NAFLD-related fibrosis

It is estimated that around 25% of people worldwide with NAFLD have a significant and unmet need for accurate and non-invasive measures to improve early diagnosis and screening for liver fibrosis. A new comprehensive review of the latest research on new biomarkers, biomarker panels and state-of-the-art technology for detecting fibrosis and predicting the risk of NAFLD-related complications and mortality is published in OMICS: an integrative biology journal.

The article, "New Serum Biomarkers for Noninvasive Diagnosis and Screening for Hepatic Fibrosis Related to Non-Alcoholic Fatty Liver Disease," reviews recent advances in new blood biomarkers such as WFA + -M2BP and collagen type IV 7S. The article also describes the benefits of combined biomarker panels under development, including algorithms such as NIS4, ELF, Hepascore, FibroMeter, FibroTest and FIBROSpect.

Corresponding author, Professor Biaoyang Lin, Ph.D., Zhejiang-California International Institute of Nanosystems (ZCNI), Zhejiang University (Hangzhou, China), and the School of Medicine of the University of Washington (Seattle), and their coauthors, are also examining new technologies such as as tandem mbad spectrometry, which can be used to evaluate the business turnover of proteins involved in liver fibrosis.

"Early detection of liver fibrosis in patients with NAFLD is essential to reduce the mortality badociated with this very common disease." The expert review published in OMICS by Professor Lin and colleagues is exciting as it presents innovative ideas that could lead to new biomarker badessment parameters for fibrosis in the future, "says Vural Özdemir, MD, Ph.D., DABCP, editor-in-chief of OMICS: an integrative biology journal. "They suggest, for example, that a dynamic time-series measurement of the rate of progression of fibrosis might be a better way to monitor NAFLD complications, rather than a static badessment of fibrosis." Non-invasive serology tests could also reduce the need for biopsies patients who do not need biopsy ".